Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene expression profiles of carotid plaques differ between patients with amaurosis fugax and those with cerebral transient ischemic attack or stroke.

Cardiovascular research·2026
Same author

Voices of those recruiting: A qualitative study on barriers and enablers to women's participation in cardiovascular trials.

Atherosclerosis·2026
Same author

Incorporating angina into the H<sub>2</sub>FPEF score improves diagnostic performance for HFpEF in women.

Open heart·2026
Same author

Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials.

European heart journal·2026
Same author

Female-Biased VSMC GRNs Predict MYH9 as Regulator of Fibrous Plaque Phenotype.

Circulation research·2026
Same author

Diagnostic Yield and Safety of Invasive Coronary Function Testing After Radial Versus Femoral Access.

Circulation. Cardiovascular interventions·2026

Related Experiment Video

Updated: Jan 21, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K

Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction.

Ariane A Sickinghe1, Suzanne J A Korporaal1, Hester M den Ruijter1

  • 1Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht, Netherlands.

Frontiers in Endocrinology
|July 24, 2019
PubMed
Summary

Post-menopausal estrogen decline may drive heart failure with preserved ejection fraction (HFpEF) by impairing cardiac microvasculature. Understanding estrogen

Keywords:
(perivascular) fibrosiscapillary rarefactionendothelial dysfunctionestrogensheart failure with preserved ejection fractionimpaired angiogenesismicrovascular dysfunctionsex differences

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Related Experiment Videos

Last Updated: Jan 21, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Gerontology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a growing syndrome linked to microvascular dysfunction.
  • Current treatments for HFpEF are lacking, necessitating further research into its underlying mechanisms.
  • Post-menopausal women are disproportionately affected by HFpEF, suggesting a role for estrogen depletion.

Purpose of the Study:

  • To explore the contribution of estrogen depletion to myocardial microvascular dysfunction in post-menopausal women.
  • To review the molecular targets of estrogen relevant to HFpEF pathogenesis.
  • To identify potential avenues for future research and therapeutic strategies.

Main Methods:

  • This review synthesizes existing literature on estrogen's effects on the cardiovascular system.
  • It examines molecular mechanisms of endothelial function, angiogenesis, and fibrosis influenced by estrogen.
  • The review correlates these mechanisms with observed HFpEF pathophysiology.

Main Results:

  • Estrogen influences the balance of vasodilating and vasoconstricting factors, impacting blood pressure regulation.
  • Estrogen enhances angiogenic capacity and mitigates fibrosis, protecting against microvascular damage.
  • Estrogen depletion post-menopause may lead to myocardial microvascular dysfunction and increased HFpEF risk.

Conclusions:

  • Estrogen plays a protective role in maintaining cardiovascular microvascular health.
  • Declining estrogen levels after menopause are a potential key factor in HFpEF development.
  • Targeting estrogen-related pathways could offer novel therapeutic approaches for HFpEF.